About Entrez
NCBI Toolbar

Text Version

Entrez PubMed Overview
Help | FAQ
Tutorials
New/Noteworthy
E-Utilities

PubMed Services
Journals Database
MeSH Database
Single Citation Matcher
Batch Citation Matcher
Clinical Queries
Special Queries
LinkOut
My NCBI

Related Resources
Order Documents
NLM Mobile
NLM Catalog
NLM Gateway
TOXNET
Consumer Health
Clinical Alerts
ClinicalTrials.gov
PubMed Central

All: 2 Review: 0

Items 1 - 2 of 2 One page.

1: Schampaert E, Cohen EA, Schluter M, Reeves F, Traboulsi M, Title LM, Kuntz RE, Popma JJ; C-SIRIUS Investigators. Related Articles, Links

The Canadian study of the sirolimus-eluting stent in the treatment of patients with long de novo lesions in small native coronary arteries (C-SIRIUS).
J Am Coll Cardiol. 2004 Mar 17;43(6):1110-5.
PMID: 15028375 [PubMed - indexed for MEDLINE]

2: Humphreys WG, Obermeier MT, Morrison RA. Related Articles, Links

Continuous blood withdrawal as a rapid screening method for determining clearance of oral bioavailability in rats.
Pharm Res. 1998 Aug;15(8):1257-61.
PMID: 9706058 [PubMed - indexed for MEDLINE]

EAST Search History

Ref #	Hits	Search Query	DBs	Default Operator	Plurals	Time Stamp
L1	3	BMS-A	USPAT	OR	OFF	2006/02/27 19:31

Google Scholar BETA BMS-A KINASE Search

Advanced Scholar Search
Scholar Preferences
Scholar Help

Scholar Results **1 - 10** of about **23** for **BMS-A KINASE**. (**0.07** seconds)

Genetic Evidence That Protease-activated Receptors Mediate Factor Xa Signaling in Endothelial Cells - group of 4 »
E Camerer, H Kataoka, M Kahn, K Lease, SR Coughlin - J Biol Chem, 2002 - jbc.org
... using antibodies to phosphorylated (pERK) or total (ERK) MAP **kinase** as indicated. ... nM), AYPGKF (500 μM), TFLLRNPNDK (100 μM). BMS200261 (**BMS**, **a** PAR1 antagonist ...
Cited by 49 - Web Search - BL Direct

Drug Eluting Stents
YL Lee, J Lee - jhu.edu
... **A** hollow tube with slots mounted on a balloon catheter in a "crimped" or ... Inhibits mTOR, a downstream protein **kinase** of the phosphatidylinositol ...
View as HTML - Web Search

Phase II Multicenter Study of the Epidermal Growth Factor Receptor Antibody Cetuximab and Cisplatin ... - group of 4 »
RS Herbst, M Arquette, DM Shin, K Dicke, EE Vokes, ... - J Clin Oncol, 2005 - jco.org
... was not associated with a change in EGFR or phosphorylated extracellular signal-regulated **kinase** expression in 10 ... Merrill S. Kies, ImClone (A), **BMS** (**A**), BMS (...
Cited by 2 - Web Search

Intracellular trafficking by Star regulates cleavage of the Drosophila EGF receptor ligand Spitz - group of 8 »
R Tsruya, A Schlesinger, A Reich, L Gabay, A Sapir ... - GENES AND DEVELOPMENT, 2002 - genesdev.org
... induction of target genes and the accumulation of activated MAP **kinase** (dpERK) (Schweitzer ... (**A**) The capacity of Star constructs to promote mSpi cleavage in S2 ...
Cited by 28 - Web Search - BL Direct

Early assessment of patients with suspected acute myocardial infarction by biochemical monitoring ... - group of 5 »
J Ellenius, T Groth, B Lindahl, L Wallentin - Clin Chem, 1997 - clinchem.org
... Fax +46 18–531202; e-mail Johan.Ellenius{at}**BMSA**.uu.se. ... Blood samples for measurement
of myoglobin, creatine **kinase** isoform MB, and troponin T were obtained ...
Cited by 6 - Web Search - BL Direct

Early and mid-term results of drug-eluting stent implantation in unprotected left main - group of

10 »
A Chieffo, G Stankovic, E Bonizzoni, E Tsagalou, I ... - Circulation, 2005 - circ.ahajournals.org
... **A** randomized study comparing surgery appears justified at present. ... Non–Q-wave MI was defined as elevation of total creatine **kinase** 2 times above the upper ...
Cited by 12 - Web Search

核因子-κB 活化在急性肺损伤发病中的作用 - group of 2 »
郭振辉， 洪新， 毛宝龄， 钱桂生， ... - 中华急诊医学杂志, 2003 - 维普资讯
... B与B的结合特性、通过核蛋白中NF-~zB与标记的．cB系列结合后的**BMSA**自显影结果，
反映了 ... JD，Gao X，Can E，et 81．It~B **kinase**一8 NF ...
Cited by 2 - Web Search

Interventional Cardiology - group of 2 »
A Chieffo, G Stankovic, E Bonizzoni, E Tsagalou, I ... - summerinseattle.com
... **A** randomized study comparing surgery appears justified at present. ... Non–Q-wave MI was defined as elevation of total creatine **kinase** 2 times above the upper ...
View as HTML - Web Search

Related Links - group of 2 »
NG Avery, JL Kaiser, DM Barnes, MJ Sharman, TP ... - The Journal of Strength and Conditioning Research - nsca.allenpress.com
... Key Words: lipid peroxidation, malondialdehyde, creatine **kinase**, delayed-onset muscle soreness ... **A** position transducer (Celesco, model PT 9510, Canoga Park, CA ...
Web Search

Prospective Native Coronary Artery Stenosis Treated with Sirolimus-Eluting Stent (ONASSIS) Registry ... - group of 6 »
V Voudris, E Alexopoulos, P Karyofillis, J Malakos ... - J Invasive Cardiol, 2005 - hmpcommunications.com
... procedure was defined as muscle-brain fraction of creatine **kinase** elevation > 3 ... **A** lower percentage of patients treated with SES received peri-procedural GP IIb ...
Cached - Web Search

Gooogle ▶
Result Page: 1 2 3 **Next**

BMS-A KINASE Search

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:SSSPTA1623SQS

PASSWORD:
TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * * * * * * Welcome to STN International * * * * * * * *
* *

NEWS 1 Web Page URLs for STN Seminar Schedule - N. America
NEWS 2 "Ask CAS" for self-help around the clock
NEWS 3 DEC 05 CASREACT(R) - Over 10 million reactions available
NEWS 4 DEC 14 2006 MeSH terms loaded in MEDLINE/LMEDLINE
NEWS 5 DEC 14 2006 MeSH terms loaded for MEDLINE file segment of TOXCENTER
NEWS 6 DEC 14 CA/CAplus to be enhanced with updated IPC codes
NEWS 7 DEC 21 IPC search and display fields enhanced in CA/CAplus with the
IPC reform
NEWS 8 DEC 23 New IPC8 SEARCH, DISPLAY, and SELECT fields in USPATFULL/
USPAT2
NEWS 9 JAN 13 IPC 8 searching in IFIPAT, IFIUDB, and IFICDB
NEWS 10 JAN 13 New IPC 8 SEARCH, DISPLAY, and SELECT enhancements added to
INPADOC
NEWS 11 JAN 17 Pre-1988 INPI data added to MARPAT
NEWS 12 JAN 17 IPC 8 in the WPI family of databases including WPIFV
NEWS 13 JAN 30 Saved answer limit increased
NEWS 14 JAN 31 Monthly current-awareness alert (SDI) frequency added to TULSA
NEWS 15 FEB 21 STN AnaVist, Version 1.1, lets you share your STN AnaVist
visualization results
NEWS 16 FEB 22 Status of current WO (PCT) information on STN
NEWS 17 FEB 22 The IPC thesaurus added to additional patent databases on STN
NEWS 18 FEB 22 Updates in EPFULL; IPC 8 enhancements added

NEWS EXPRESS FEBRUARY 15 CURRENT VERSION FOR WINDOWS IS V8.01a,
CURRENT MACINTOSH VERSION IS V6.0c(ENG) AND V6.0Jc(JP),
AND CURRENT DISCOVER FILE IS DATED 19 DECEMBER 2005.
V8.0 AND V8.01 USERS CAN OBTAIN THE UPGRADE TO V8.01a AT

http://download.cas.org/express/v8.0-Discover/

```
 NEWS HOURS     STN Operating Hours Plus Help Desk Availability
 NEWS INTER     General Internet Information
 NEWS LOGIN     Welcome Banner and News Items
 NEWS PHONE     Direct Dial and Telecommunication Network Access to STN
 NEWS WWW       CAS World Wide Web Site (general information)

Enter NEWS followed by the item number or name to see news on that
specific topic.

  All use of STN is subject to the provisions of the STN Customer
  agreement.  Please note that this agreement limits use to scientific
  research.  Use for software development or design or implementation
  of commercial gateways or other similar uses is prohibited and may
  result in loss of user privileges and other penalties.

  * * * * * * * * * * * * * * STN  Columbus  * * * * * * * * * * * * * *
* *

FILE 'HOME' ENTERED AT 20:23:45 ON 27 FEB 2006

=> File Medline EMBASE Biosis Caplus
COST IN U.S. DOLLARS                                SINCE FILE      TOTAL
                                                       ENTRY    SESSION
FULL ESTIMATED COST                                     0.21       0.21

FILE 'MEDLINE' ENTERED AT 20:23:56 ON 27 FEB 2006

FILE 'EMBASE' ENTERED AT 20:23:56 ON 27 FEB 2006
Copyright (c) 2006 Elsevier B.V. All rights reserved.

FILE 'BIOSIS' ENTERED AT 20:23:56 ON 27 FEB 2006
Copyright (c) 2006 The Thomson Corporation

FILE 'CAPLUS' ENTERED AT 20:23:56 ON 27 FEB 2006
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2006 AMERICAN CHEMICAL SOCIETY (ACS)

=> s EphA2 (4A) expression
L1          208 EPHA2 (4A) EXPRESSION

=> s Kinase (3A) inhibitor
L2       163473 KINASE (3A) INHIBITOR

=> s l1 and l2
L3            8 L1 AND L2

=> duplicate
ENTER REMOVE, IDENTIFY, ONLY, OR (?):remove
ENTER L# LIST OR (END):l3
```

```
DUPLICATE PREFERENCE IS 'MEDLINE, EMBASE, BIOSIS, CAPLUS'
KEEP DUPLICATES FROM MORE THAN ONE FILE?  Y/(N):n
PROCESSING COMPLETED FOR L3
L4             5 DUPLICATE REMOVE L3 (3 DUPLICATES REMOVED)

=> d l4 1-5 bib ab

L4   ANSWER 1 OF 5  CAPLUS  COPYRIGHT 2006 ACS on STN
AN   2005:161005  CAPLUS
DN   142:254576
TI   Inhibitors of EphA2, PCDGF, and HAAH for combination therapy and
diagnosis
     of prevention of hyperproliferative disorder, cancer and
metastasis
IN   Kinch, Michael S.; Carles-Kinch, Kelly; Kiener, Peter;
Langermann,
     Solomon; Mccarthy, Michael P.; Tice, David; Woessner, Richard
PA   Medimmune, Inc., USA
SO   PCT Int. Appl., 177 pp.
     CODEN: PIXXD2
DT   Patent
LA   English
FAN.CNT 1
     PATENT NO.          KIND   DATE        APPLICATION NO.
DATE
     ---------------     ----   --------    --------------------
--------
PI   WO 2005016381        A2    20050224    WO 2004-US23097
20040716
         W:  AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ,
CA, CH,
             CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI,
GB, GD,
             GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR,
KZ, LC,
             LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ,
NA, NI,
             NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK,
SL, SY,
             TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA,
ZM, ZW
        RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM,
ZW, AM,
             AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ,
DE, DK,
             EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT,
RO, SE,
             SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML,
MR, NE,
             SN, TD, TG
PRAI US 2003-489036P      P     20030721
AB   The present invention relates to methods and compns. designed
for the
```

treatment, management, or prevention of a hyperproliferative disorder, particularly cancer, more particularly metastatic cancer. The methods of the invention comprise the administration of an effective amount of one or more agents that decrease/inhibit **EphA2** receptor tyrosine kinase (**EphA2**) **expression** or activity in combination with one or more agents that decrease/inhibit PC cell derived growth factor (PCDGF) or human aspartyl (asparaginyl) β-hydroxylase (HAAH) expression or activity. In another embodiment, the methods of the invention comprise the administration of an effective amount of one or more EphA2, PCDGF, and/or HAAH agents of the invention that inhibit cancer cell colony formation in soft agar or tubular network formation in three-dimensional basement membrane or extracellular matrix preparation The invention also provides pharmaceutical compns. comprising one or more EphA2 agents of the invention in combination with one or more PCDGF agents of the invention and/or one or more HAAH agents of the invention. In some embodiments, the agents of the invention can be administered with other cancer therapeutic agents that are not EphA2-, PCDGF-, or HAAH-based. Diagnostic methods and methods for screening for therapeutically useful agents of the invention are also provided.

L4 ANSWER 2 OF 5 CAPLUS COPYRIGHT 2006 ACS on STN
AN 2005:1020555 CAPLUS
DN 143:320266
TI Genes with differential expression profile between human dental pulp stem cells and mesenchymal stem cells and use for regenerating tooth germ
IN Ueda, Minoru; Yamada, Yoichi
PA Hitachi Medical Corp., Japan
SO Jpn. Kokai Tokkyo Koho, 246 pp.
CODEN: JKXXAF
DT Patent
LA Japanese
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE

PI	JP 2005253442	A2	20050922	JP 2004-111582 20040309
PRAI	JP 2004-111582		20040309	

AB The present invention relates to a group of genes whose expression profile are different between human dental pulp stem cells and mesenchymal stem cells, as well as a method for regenerating tooth germ using these genes. According to the present invention, the gene expression profiles and cluster anal. between human dental pulp stem cells (hDPSCs) and mesenchymal stem cells (hMSCs) as representative populations of odontoprogenitor and osteoprogenitor cell were revealed, and a group of genes whose expression profile are different between human dental pulp stem cells and mesenchymal stem cells was identified. By utilizing the groups of the genes of the present invention together with the dental pulp stem cells and mesenchymal stem cells, hard tissue such as tooth germ, dental pulp, dentin or bone can be regenerated. The present inventors investigated the gene expression profiles and cluster anal. between human dental pulp stem cells (hDPSCs) and mesenchymal stem cells (hMSCs) as representative populations of odontoprogenitor and osteoprogenitor cells, resp. At first, the present inventors confirmed the differential expression of Alkaline phosphatase (ALP) activity, Dentin matrix protein 1 (DMP 1), Dentin phosphosialoprotein (DSPP) using by real time reverse-transcriptase polymerase chain reaction (RT-PCR) in total RNA from primary cultures. The number of genes in hDPSCs(I) that were up-regulated by 2>-fold, compared to hMSCs, was 614 (Table, IV). On the other band, the number of genes down regulated by <2-fold in hDPSCs (I) was 296 (Table III, IV).

L4 ANSWER 3 OF 5 CAPLUS COPYRIGHT 2006 ACS on STN
AN 2005:1097554 CAPLUS
DN 144:168423
TI Strong expression of ID1 protein is associated with decreased survival,

increased **expression** of ephrin-A1/**EPHA2**, and reduced thrombospondin-1 in malignant melanoma

AU Straume, O.; Akslen, L. A.
CS The Gade Institute, Section for Pathology, University of Bergen, Bergen, Norway

SO British Journal of Cancer (2005), 93(8), 933-938
CODEN: BJCAAI; ISSN: 0007-0920
PB Nature Publishing Group
DT Journal
LA English

AB The ID1 protein, an inhibitor of basic helix-loop-helix transcription factors, has been involved in multiple cellular processes including cell cycle regulation, apoptosis, and angiogenesis. To evaluate the importance of ID1 in malignant melanoma, tumor cell expression was examined by immunohistochem. in 119 cases of nodular melanoma using tissue microarray technique, and related to multiple tumor markers including proliferation, p16 expression, angiogenesis and patient survival. Strong ID1 expression was significantly associated with increased tumor thickness, and significantly reduced survival. Also, increased ID1 was associated with loss of thrombospondin-1 (TSP-1) expression, a known inhibitor of angiogenesis, and increased intensity of ephrin-A1 and its receptor EPHA2. Presence of BRAF mutations was related to strong ID1 expression, but there was no relationship with p16 protein expression. Further, no significant correlation was found between ID1 and microvessel d. In conclusion, our study supports a significant role of the ID1 protein in melanoma progression and patient prognosis. The absence of correlation with p16 protein expression and angiogenesis suggests that other regulatory pathways and mechanisms might be influenced by ID1 in melanomas. An inverse relation between ID1 and TSP-1 expression support an important role of ID1 in the regulation of this complex multitarget protein.

RE.CNT 40 THERE ARE 40 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 4 OF 5 CAPLUS COPYRIGHT 2006 ACS on STN
AN 2004:308529 CAPLUS
DN 140:333599
TI Gene expression profile of human and mouse genes in atopic dermatitis and
psoriasis patients and its use for diagnosis, therapy, and drug screening
IN Itoh, Mikito; Ogawa, Kaoru; Shinagawa, Akira; Sudo, Hajime; Ogawa,
Hideoki; Ra, Chisei; Mitsuishi, Kouichi
PA Genox Research, Inc., Japan; Juntendo University
SO PCT Int. Appl., 611 pp.
CODEN: PIXXD2
DT Patent
LA Japanese
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004031386	A1	20040415	WO 2003-JP9808	20030801
AU 2003252326	A1	20040423	AU 2003-252326	20030801

PI WO 2004031386 A1 20040415 WO 2003-JP9808 20030801
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,
CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,
GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS,
LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG,
PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR,
TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY,
KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES,
FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR,
BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG
AU 2003252326 A1 20040423 AU 2003-252326 20030801
PRAI JP 2002-229318 A 20020806
JP 2003-136543 A 20030514
WO 2003-JP9808 W 20030801
AB This invention provides gene expression profile between a rash site and a
no-rash site in a patient with atopic dermatitis or a patient with
psoriasis. The invention also provides gene expression profile between a

no-rash site in such a disease and a normal subject. Animal models,
particularly mouse for those diseases are also claimed. The gene
expression profile provided in this invention can be used for diagnosis,
therapy, and drug screening for atopic dermatitis and psoriasis.
RE.CNT 8 THERE ARE 8 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 5 OF 5 MEDLINE on STN DUPLICATE 1
AN 2002707338 MEDLINE
DN PubMed ID: 12467573
TI Structures of the cancer-related Aurora-A, FAK, and EphA2 protein kinases
from nanovolume crystallography.
AU Nowakowski Jacek; Cronin Ciaran N; McRee Duncan E; Knuth Mark W; Nelson
Christian G; Pavletich Nikola P; Rogers Joe; Sang Bi-Ching; Scheibe Daniel
N; Swanson Ronald V; Thompson Devon A
CS Syrrx, Inc., 10410 Science Center Drive, San Diego, CA 92121, USA..
jacek.nowakoski@syrrx.com
SO Structure (Cambridge, Mass. : 2001), (2002 Dec) Vol. 10, No. 12, pp.
1659-67.
Journal code: 101087697. ISSN: 0969-2126.
CY United States
DT Journal; Article; (JOURNAL ARTICLE)
LA English
FS Priority Journals
OS PDB-1MP8; PDB-1MQ4; PDB-1MQB
EM 200305
ED Entered STN: 20021217
Last Updated on STN: 20030529
Entered Medline: 20030528
AB Protein kinases are important drug targets in human cancers, inflammation,
and metabolic diseases. This report presents the structures of kinase
domains for three cancer-associated protein kinases: ephrin receptor A2
(EphA2), focal adhesion kinase (FAK), and Aurora-A. The
expression profiles of **EphA2**, FAK, and Aurora-A in
carcinomas suggest that **inhibitors** of these **kinases**
may have inherent potential as therapeutic agents. The structures were
determined from crystals grown in nanovolume droplets, which produced
high-resolution diffraction data at 1.7, 1.9, and 2.3 A for FAK, Aurora-A,
and EphA2, respectively. The FAK and Aurora-A structures are the first

determined within two unique subfamilies of human kinases, and all three structures provide new insights into kinase regulation and the design of selective inhibitors.

EAST Search History

Ref #	Hits	Search Query	DBs	Default Operator	Plurals	Time Stamp
L1	2	EphA2 near4 expression	USPAT	OR	OFF	2006/02/27 20:17

About Entrez
NCBI Toolbar

Text Version

Entrez PubMed Overview
Help | FAQ
Tutorials
New/Noteworthy
E-Utilities

PubMed Services
Journals Database
MeSH Database
Single Citation Matcher
Batch Citation Matcher
Clinical Queries
Special Queries
LinkOut
My NCBI

Related Resources
Order Documents
NLM Mobile
NLM Catalog
NLM Gateway
TOXNET
Consumer Health
Clinical Alerts
ClinicalTrials.gov
PubMed Central

All: 5 Review: 0

Items 1 - 5 of 5 One page.

1: McLaughlin T, O'Leary DD. Related Articles, Links

Functional consequences of coincident expression of EphA receptors and ephrin-A ligands.
Neuron. 1999 Apr;22(4):636-9. No abstract available.
PMID: 10230779 [PubMed - indexed for MEDLINE]

2: Chen J, Ruley HE. Related Articles, Links

An enhancer element in the EphA2 (Eck) gene sufficient for rhombomere-specific expression is activated by HOXA1 and HOXB1 homeobox proteins.
J Biol Chem. 1998 Sep 18;273(38):24670-5.
PMID: 9733765 [PubMed - indexed for MEDLINE]

3: Kikawa KD, Vidale DR, Van Etten RL, Kinch MS. Related Articles, Links

Regulation of the EphA2 kinase by the low molecular weight tyrosine phosphatase induces transformation.
J Biol Chem. 2002 Oct 18;277(42):39274-9. Epub 2002 Aug 6.
PMID: 12167657 [PubMed - indexed for MEDLINE]

4: Zelinski DP, Zantek ND, Walker-Daniels J, Peters MA, Taparowsky EJ, Kinch MS. Related Articles, Links

Estrogen and Myc negatively regulate expression of the EphA2 tyrosine kinase.
J Cell Biochem. 2002;85(4):714-20.
PMID: 11968011 [PubMed - indexed for MEDLINE]

5: Dohn M, Jiang J, Chen X. Related Articles, Links

Receptor tyrosine kinase EphA2 is regulated by p53-family proteins and induces apoptosis.
Oncogene. 2001 Oct 4;20(45):6503-15.
PMID: 11641774 [PubMed - indexed for MEDLINE]

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:SSSPTA1623SQS

PASSWORD:
TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * * * * * * Welcome to STN International * * * * * * * *
* *

NEWS 1 Web Page URLs for STN Seminar Schedule - N. America
NEWS 2 "Ask CAS" for self-help around the clock
NEWS 3 DEC 05 CASREACT(R) - Over 10 million reactions available
NEWS 4 DEC 14 2006 MeSH terms loaded in MEDLINE/LMEDLINE
NEWS 5 DEC 14 2006 MeSH terms loaded for MEDLINE file segment of TOXCENTER
NEWS 6 DEC 14 CA/CAplus to be enhanced with updated IPC codes
NEWS 7 DEC 21 IPC search and display fields enhanced in CA/CAplus with the
IPC reform
NEWS 8 DEC 23 New IPC8 SEARCH, DISPLAY, and SELECT fields in USPATFULL/
USPAT2
NEWS 9 JAN 13 IPC 8 searching in IFIPAT, IFIUDB, and IFICDB
NEWS 10 JAN 13 New IPC 8 SEARCH, DISPLAY, and SELECT enhancements added to
INPADOC
NEWS 11 JAN 17 Pre-1988 INPI data added to MARPAT
NEWS 12 JAN 17 IPC 8 in the WPI family of databases including WPIFV
NEWS 13 JAN 30 Saved answer limit increased
NEWS 14 JAN 31 Monthly current-awareness alert (SDI) frequency
added to TULSA
NEWS 15 FEB 21 STN AnaVist, Version 1.1, lets you share your STN AnaVist
visualization results
NEWS 16 FEB 22 Status of current WO (PCT) information on STN
NEWS 17 FEB 22 The IPC thesaurus added to additional patent databases on STN
NEWS 18 FEB 22 Updates in EPFULL; IPC 8 enhancements added

NEWS EXPRESS FEBRUARY 15 CURRENT VERSION FOR WINDOWS IS V8.01a,
CURRENT MACINTOSH VERSION IS V6.0c(ENG) AND V6.0Jc(JP),
AND CURRENT DISCOVER FILE IS DATED 19 DECEMBER 2005.
V8.0 AND V8.01 USERS CAN OBTAIN THE UPGRADE TO V8.01a AT

http://download.cas.org/express/v8.0-Discover/

NEWS HOURS	STN Operating Hours Plus Help Desk Availability
NEWS INTER	General Internet Information
NEWS LOGIN	Welcome Banner and News Items
NEWS PHONE	Direct Dial and Telecommunication Network Access to STN
NEWS WWW	CAS World Wide Web Site (general information)

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

* * * * * * * * * * * * * * STN Columbus * * * * * * * * * * * * * *

FILE 'HOME' ENTERED AT 19:40:58 ON 27 FEB 2006

=> File Medline EMBASE Biosis Caplus

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	0.21	0.21

FILE 'MEDLINE' ENTERED AT 19:41:07 ON 27 FEB 2006

FILE 'EMBASE' ENTERED AT 19:41:07 ON 27 FEB 2006

FILE 'BIOSIS' ENTERED AT 19:41:07 ON 27 FEB 2006

FILE 'CAPLUS' ENTERED AT 19:41:07 ON 27 FEB 2006

=> s BMS-A
L1 24 BMS-A

=> s l2 (4A) kinase
L2 NOT FOUND
The L-number entered could not be found. To see the definition of L-numbers, enter DISPLAY HISTORY at an arrow prompt (=>).

=> s l1 (4A) kinase
L2 4 L1 (4A) KINASE

=> duplicate

ENTER REMOVE, IDENTIFY, ONLY, OR (?):remove
ENTER L# LIST OR (END):l1
DUPLICATE PREFERENCE IS 'MEDLINE, EMBASE, BIOSIS, CAPLUS'
KEEP DUPLICATES FROM MORE THAN ONE FILE? Y/(N):n
PROCESSING COMPLETED FOR L1
L3 18 DUPLICATE REMOVE L1 (6 DUPLICATES REMOVED)

=> s l3 (4A) kinase
L4 4 L3 (4A) KINASE

=> d l4 1-4 bib ab

L4 ANSWER 1 OF 4 CAPLUS COPYRIGHT 2006 ACS on STN
AN 2006:120539 CAPLUS
DN 144:164210
TI Gene expression biomarkers for predicting activity of compounds that
interact with protein tyrosine kinases and pathways in breast cells
IN Huang, Fei; Han, Xia; Reeves, Karen A.; Amler, Lukas C.; Fairchild, Craig
R.; Lee, Francis Y.; Shaw, Peter
PA USA
SO U.S. Pat. Appl. Publ., 74 pp., Cont.-in-part of U.S. Ser. No. 648,593.
CODEN: USXXCO
DT Patent
LA English
FAN.CNT 2

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2006029944	A1	20060209	US 2005-72175	20050304
US 2004106132	A1	20040603	US 2003-648593	20030826
PRAI US 2002-406385P	P	20020827		
US 2003-648593	A2	20030826		

AB The present invention describes polynucleotides that have been discovered
to correlate to the relative intrinsic sensitivity or resistance of cells,
e.g., breast cell lines, to treatment with compds. that interact with and
modulate, e.g., inhibit, protein tyrosine kinases. The protein tyrosine
kinase inhibitor compound **BMS-A** was tested for
cytotoxicity in vitro against a panel of 23 human breast cell lines.
Expression profiling data of 44,792 probe sets represented on the
Affymetrix HG-U133 array set were obtained for the 23 untreated breast

cell lines. One hundred thirty-seven genes are identified whose expression is correlated with sensitivity/resistance of the cell lines and IC50 values. These polynucleotides have been shown, through a weighted voting cross-validation program, to have utility in predicting the resistance and sensitivity of breast cell lines to **BMS-A** and other protein tyrosine **kinase** inhibitor compds. The expression level or phosphorylation status of some polynucleotides is regulated by treatment with a particular protein tyrosine kinase inhibitor compound, thus indicating that these polynucleotides are involved in the protein tyrosine kinase signal transduction pathway. Such polynucleotides, whose expression levels correlate highly with drug sensitivity or resistance and which are modulated by treatment with the compds., comprise polynucleotide predictor or marker sets useful in methods of predicting drug response, and as prognostic or diagnostic indicators in disease management.

L4 ANSWER 2 OF 4 CAPLUS COPYRIGHT 2006 ACS on STN
AN 2006:29606 CAPLUS
DN 144:121754
TI Gene expression profile for predicting activity of compounds that interact with and/or modulate protein tyrosine kinases and/or protein tyrosine pathways in lung cancer cells
IN Huang, Fei; Reeves, Karen A.; Han, Xia; Fairchild, Craig R.; Shaw, Peter
PA Bristol-Myers Squibb Company, USA
SO PCT Int. Appl., 130 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2006005035	A2	20060112	WO 2005-US23687	20050629

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD,

GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ,
LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA,
NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK,
SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU,
ZA, ZM, ZW
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE,
IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF,
CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM,
KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG,
KZ, MD, RU, TJ, TM
US 2006019284 A1 20060126 US 2005-169041 20050628
PRAI US 2004-584405P P 20040630
AB The present invention describes polynucleotides that have been discovered
to correlate to the relative intrinsic sensitivity or resistance of cells,
e.g., lung cell lines, to treatment with compds. that interact with and
modulate, e.g., inhibit, protein tyrosine kinases, such as, for example,
members of the Src family of tyrosine kinases, e.g., Src, Fgr, Fyn, Yes,
Blk, Hck, Lck and Lyn, as well as other protein tyrosine kinases,
including, Bcr-abl, Jak, PDGFR, c-kit and Ephr. These polynucleotides
have been shown, through a weighted voting cross validation program, to
have utility in predicting the resistance and sensitivity of lung cell
lines to the compds. The expression level of some polynucleotides is
regulated by treatment with a particular protein tyrosine kinase inhibitor
compound, thus indicating that these polynucleotides are involved in the
protein tyrosine kinase signal transduction pathway, e.g., Src tyrosine
kinase. The Affymetrix human HG-U133 GeneChip set of over 44,792 probe
sets was used to identify 129 polynucleotides that are highly correlated
with a resistance/sensitivity phenotype classification of 23 lung cell

lines subjected to treatment with the protein tyrosine **kinase** inhibitor compound **BMS-A**. Of the 129 predictor polynucleotides, 81 polynucleotides highly expressed in the cell lines were classified as sensitive to BMS-A, while 48 polynucleotides highly expressed in the cell lines were classified as resistant to BMS-A. Such polynucleotides, whose expression levels correlate highly with drug sensitivity or resistance and which are modulated by treatment with the compds., comprise polynucleotide predictor or marker sets useful in methods of predicting drug response, and as prognostic or diagnostic indicators in disease management, particularly in those disease areas, e.g., lung cancer, in which signaling through the protein tyrosine kinase pathway, such as the Src tyrosine kinase pathway, is involved with the disease process.

L4 ANSWER 3 OF 4 CAPLUS COPYRIGHT 2006 ACS on STN
AN 2004:203933 CAPLUS
DN 140:247003
TI Expressed polynucleotides markers for predicting activity of compounds that interact with and/or modulate protein tyrosine kinases and/or protein tyrosine kinase pathways in breast cells
IN Huang, Fei; Han, Xia; Reeves, Karen A.; Amler, Lucas; Fairchild, Craig R.; Lee, Francis Y.; Shaw, Peter
PA Bristol-Myers Squibb Company, USA
SO PCT Int. Appl., 649 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 2

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004020583	A2	20040311	WO 2003-US26491	20030826
WO 2004020583	C1	20050428		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,

GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR,
LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM,
PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN,
TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY,
KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES,
FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR,
BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG
EP 1572957 A2 20050914 EP 2003-770252 20030826
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK
PRAI US 2002-406385P P 20020827
WO 2003-US26491 W 20030826

AB The present invention describes polynucleotides that have been discovered to correlate to the relative intrinsic sensitivity or resistance of cells (e.g., breast cell lines) to treatment with compds. that interact with and modulate (e.g., inhibit) protein tyrosine kinases, such as, for example, members of the Src family of tyrosine kinases (e.g., Src, Fgr, Fyn, Yes, Blk, Hck, Lck and Lyn), as well as other protein tyrosine kinases, including, Bcr-abl, Jak, PDGFR, c-kit and Eph receptors. These polynucleotides have been shown, through a weighted voting cross validation program, to have utility in predicting the resistance and sensitivity of breast cell lines to the compds. Thus, 137 polynucleotides are provided that highly correlate with a resistance/sensitivity phenotype classification of 23 breast cell lines for the protein tyrosine **kinase** inhibitor **BMS-A**. The expression level or phosphorylation status of some polynucleotides is regulated by treatment with a particular protein tyrosine kinase inhibitor compound, thus indicating that these polynucleotides are involved in the protein tyrosine kinase signal transduction pathway. Such polynucleotides, whose expression levels correlate highly with drug sensitivity or resistance and

which are modulated by treatment with the compds., comprise polynucleotide predictor or marker sets useful in methods of predicting drug response, and as prognostic or diagnostic indicators in disease management, particularly in those disease areas, e.g., breast cancer, in which signaling through the protein tyrosine kinase pathway is involved with the disease process.

L4 ANSWER 4 OF 4 CAPLUS COPYRIGHT 2006 ACS on STN
AN 2003:591309 CAPLUS
DN 139:128005
TI Polynucleotides and polypeptides useful in screening compounds interacting with protein tyrosine kinases and/or protein tyrosine kinase pathways in drug-sensitive and drug-resistant colon cells
IN Huang, Fei; Fairchild, Craig R.; Lee, Francis Y.; Shaw, Peter
PA Bristol-Myers Squibb Company, USA
SO PCT Int. Appl., 139 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003062395	A2	20030731	WO 2003-US1981	20030117
WO 2003062395	A3	20050407		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

EP 1534739 A2 20050601 EP 2003-707494 20030117
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK
JP 2005523688 T2 20050811 JP 2003-562263 20030117
PRAI US 2002-350061P P 20020118
WO 2003-US1981 W 20030117
AB The present invention describes polynucleotides and polypeptides that have been discovered to correlate to the relative intrinsic sensitivity or resistance of cells, e.g., colon cell lines, to treatment with compds. that interact with and inhibit src tyrosine kinases. These polynucleotides and polypeptides have been shown, through a weighted voting cross-validation program, to have utility in predicting the intrinsic resistance and sensitivity of colon cell lines to these compds. Oligonucleotide microarrays (the Affymetrix HG-U95Av2 array) were utilized to measure the expression levels of >12,000 polynucleotides and polypeptides in a panel of 31 untreated colon cell lines for which the drug sensitivity to four src **kinase** inhibitor compds. (**BMS-A**, BMS-B, BMS-C, BMS-D) was determined using an in vitro cytotoxicity assay to determination IC50. Such polynucleotides and polypeptides whose expression levels correlate highly with drug sensitivity or resistance comprise predictor or marker sets of polynucleotides and polypeptides that are useful in methods of predicting drug response and as prognostic or diagnostic indicators in disease management, particularly in those disease areas in which signaling through src tyrosine kinase of the src tyrosine kinase pathway is involved with the disease process.

=> S L3 NOT L4
L5 14 L3 NOT L4

=> d l5 1-14 bib

L5 ANSWER 1 OF 14 MEDLINE on STN
AN 2004135848 MEDLINE
DN PubMed ID: 15028375

TI The Canadian study of the sirolimus-eluting stent in the treatment of
patients with long de novo lesions in small native coronary arteries
(C-SIRIUS).
AU Schampaert Erick; Cohen Eric A; Schluter Michael; Reeves Francois;
Traboulsi Mouhieddin; Title Lawrence M; Kuntz Richard E; Popma Jeffrey J
CS Hopital du Sacre-Coeur de Montreal, 5400 Bl. Gouin O., Montreal, Quebec,
Canada H4J 1C5. (C-SIRIUS Investigators).
erick.schaempaert.hsc@ssss.gouv.
qc.ca
SO Journal of the American College of Cardiology, (2004 Mar 17) Vol. 43, No.
6, pp. 1110-5.
Journal code: 8301365. ISSN: 0735-1097.
CY United States
DT (CLINICAL TRIAL)
Journal; Article; (JOURNAL ARTICLE)
(MULTICENTER STUDY)
(RANDOMIZED CONTROLLED TRIAL)
LA English
FS Abridged Index Medicus Journals; Priority Journals
EM 200404
ED Entered STN: 20040319
Last Updated on STN: 20040407
Entered Medline: 20040406

L5 ANSWER 2 OF 14 MEDLINE on STN
AN 2002473559 MEDLINE
DN PubMed ID: 12235503
TI [Burning mouth].
Mundbrennen.
AU Witt E; Palla S
CS Klinik fur Kaufunktionsstorungen und Totalprothetik, Zentrum fur Zahn-,
Mund- und Kieferheilkunde, Universitat Zurich, Switzerland.
SO Schmerz (Berlin, Germany), (2002 Sep) Vol. 16, No. 5, pp. 389-94. Ref: 67
Journal code: 8906258. ISSN: 0932-433X.
CY Germany: Germany, Federal Republic of
DT Journal; Article; (JOURNAL ARTICLE)
General Review; (REVIEW)
LA German
FS Priority Journals
EM 200212
ED Entered STN: 20020918
Last Updated on STN: 20021218
Entered Medline: 20021213

L5 ANSWER 3 OF 14 MEDLINE on STN
AN 1998371306 MEDLINE
DN PubMed ID: 9706058
TI Continuous blood withdrawal as a rapid screening method for determining
clearance of oral bioavailability in rats.
AU Humphreys W G; Obermeier M T; Morrison R A
CS Department of Metabolism and Pharcokinetics, Bristol-Meyers Squibb
Pharmaceutical Research Institute, Princeton, New Jersey 08543, USA..
humphrew@bms.com
SO Pharmaceutical research, (1998 Aug) Vol. 15, No. 8, pp. 1257-61.

Journal code: 8406521. ISSN: 0724-8741.
CY United States
DT Journal; Article; (JOURNAL ARTICLE)
LA English
FS Priority Journals
EM 199810
ED Entered STN: 19981029
Last Updated on STN: 19981029
Entered Medline: 19981020

L5 ANSWER 4 OF 14 MEDLINE on STN
AN 90000961 MEDLINE
DN PubMed ID: 2789896
TI Oral medicine in practice: burning mouth syndrome.
AU Lamey P J; Lewis M A
SO British dental journal, (1989 Sep 23) Vol. 167, No. 6, pp. 197-200.
Journal code: 7513219. ISSN: 0007-0610.
CY ENGLAND: United Kingdom
DT Journal; Article; (JOURNAL ARTICLE)
LA English
FS Dental Journals; Priority Journals
EM 198911
ED Entered STN: 19900328
Last Updated on STN: 19900328
Entered Medline: 19891109

L5 ANSWER 5 OF 14 EMBASE
AN 2000259284 EMBASE
TI [Conditions of selection of 'thymidine analogue mutations' (TAMs) in naive
patients receiving different antiretroviral combinations including d4T].
CONDITIONS DE SELECTION DES << THYMIDINES ANALOGUES MUTATIONS >> (TAMS)
CHEZ DES PATIENTS NAIFS TRAITES PAR DIFFERENTES COMBINAISONS INCLUANT LA

D4T.
AU Mouroux M.; Izopet J.; Descamps D.; Delaugerre C.; Yvon-Groussin A.;
Angleraud F.; Coutellier A.; Bonmarchand M.; Valantin M.A.; Matheron S.;
Agut H.; Katlama C.; Brun-Vezinet F.; Calvez V.
CS M. Mouroux, Laboratoire de Virologie, Hopital Pitie-Salpetriere, 83,
boulevard de l'Hopital, 75013 Paris, France
SO Pathologie Biologie, (2000) Vol. 48, No. 5, pp. 508-512. .
Refs: 14
ISSN: 0369-8114 CODEN: PTBIAN
CY France
DT Journal; Conference Article
FS 004 Microbiology
037 Drug Literature Index
LA French
SL English; French
ED Entered STN: 20000810
Last Updated on STN: 20000810

L5 ANSWER 6 OF 14 EMBASE COPYRIGHT (c) 2006 Elsevier B.V. All rights
reserved on STN
AN 1999133274 EMBASE
TI [Psychopharmacological treatment of burning mouth syndrome (**BMS**). **A** study on a sample of 121 patients].
TRATTAMENT PSICOFARMACOLOGICO DELLA BURNING MOUTH SYNDROME (BMS) STUDIO SU
DI UN CAMPIONE DI 121 PAZIENTI.
AU Bogetto F.; Revello R.B.; Ferro G.; Maina G.; Ravizza L.
CS F. Bogetto, Clinica Psichiatrica, Via Cherasco, 11, 10126 Torino, Italy
SO Minerva Psichiatrica, (1999) Vol. 40, No. 1, pp. 1-10. .
Refs: 60
ISSN: 0374-9320 CODEN: MPSIDG
CY Italy
DT Journal; Article
FS 032 Psychiatry
037 Drug Literature Index
LA Italian
SL English; Italian
ED Entered STN: 19990510
Last Updated on STN: 19990510

L5 ANSWER 7 OF 14 EMBASE COPYRIGHT (c) 2006 Elsevier B.V. All rights
reserved on STN
AN 97363002 EMBASE
DN 1997363002
TI Case study: Investigation into the subjective strain at two differently

designed automobile assembly workplaces.
AU Schutte M.; Schuder D.
CS M. Schutte, Institut fur Arbeitsphysiologie, Universitat Dortmund,
Abteilung Ergonomie, Ardeystrasse 67, D-44139 Dortmund, Germany
SO International Journal of Industrial Ergonomics, (1997) Vol. 20, No. 5, pp.
413-422. .
Refs: 23
ISSN: 0169-8141 CODEN: IJIEE5
PUI S 0169-8141(96)00091-1
CY Netherlands
DT Journal; Article
FS 035 Occupational Health and Industrial Medicine
LA English
SL English
ED Entered STN: 971212
Last Updated on STN: 971212

L5 ANSWER 8 OF 14 BIOSIS COPYRIGHT (c) 2006 The Thomson Corporation on STN
AN 2005:190830 BIOSIS
DN PREV200500192696
TI Species and pH dependent enzyme hydrolysis: Importance of pH control
during sample analysis.
AU Fura, Aberra [Reprint Author]; Vyas, Viral; Humphreys, W. Griffith
CS Pharmaceut Res InstDept Metab and Pharmacokinet, Bristol Myers Squibb Co,
Princeton, NJ, 08534, USA
SO Drug Metabolism Reviews, (August 2004) Vol. 36, No. Suppl. 1, pp. 203.
print.
Meeting Info.: 7th International Meeting of the International Society for
the Study of Xenobiotics. Vancouver, BC, Canada. August 29-September 02,
2004. International Society for the Study of Xenobiotics.
ISSN: 0360-2532 (ISSN print).
DT Conference; (Meeting)
Conference; Abstract; (Meeting Abstract)
LA English
ED Entered STN: 25 May 2005
Last Updated on STN: 25 May 2005

L5 ANSWER 9 OF 14 BIOSIS COPYRIGHT (c) 2006 The Thomson Corporation on STN
AN 2003:278321 BIOSIS
DN PREV200300278321
TI Activity of BMS284-756 against Streptococcus pneumoniae and viridans group

streptococci.
AU Houssaye, S. [Reprint Author]; Gutmann, L. [Reprint Author]; Varon, E.
[Reprint Author]
CS Centre National de Reference des Pneumocoques, Hopital Europeen G.
Pompidou, Paris, France
SO Abstracts of the Interscience Conference on Antimicrobial Agents and
Chemotherapy, (2002) Vol. 42, pp. 153. print.
Meeting Info.: 42nd Interscience Conference on Antimicrobial Agents and
Chemotherapy. San Diego, CA, USA. September 27-30, 2002. American Society
for Microbiology.
DT Conference; (Meeting)
Conference; Abstract; (Meeting Abstract)
LA English
ED Entered STN: 11 Jun 2003
Last Updated on STN: 11 Jun 2003

L5 ANSWER 10 OF 14 BIOSIS COPYRIGHT (c) 2006 The Thomson Corporation on
STN
AN 2001:320612 BIOSIS
DN PREV200100320612
TI Butterfly numbers and weather: Predicting historical trends in abundance
and the future effects of climate change.
AU Roy, D. B. [Reprint author]; Rothery, P.; Moss, D.; Pollard, E.; Thomas,
J. A.
CS Centre for Ecology and Hydrology, Monks Wood, Abbots Ripton, Huntingdon,
Cambridgeshire, PE28 2LS, UK
dbr@ceh.ac.uk
SO Journal of Animal Ecology, (March, 2001) Vol. 70, No. 2, pp. 201-217.
print.
CODEN: JAECAP. ISSN: 0021-8790.
DT Article
LA English
ED Entered STN: 4 Jul 2001
Last Updated on STN: 19 Feb 2002

L5 ANSWER 11 OF 14 BIOSIS COPYRIGHT (c) 2006 The Thomson Corporation on
STN
AN 2000:536953 BIOSIS
DN PREV200000536953
TI Antimicrobial activity of BMS 284756 (**BMS**), **a** new
desfluoroquinolone, tested against S. pneumoniae (SPN), H. influenzae

(HI), and M. catarrhalis (MCAT) isolates for SENTRY antimicrobial surveillance program (Latin America, 1999).
AU Gales, A. C. [Reprint author]; Sader, H. S.; Jones, R. N. [Reprint author]
CS Univ. of Iowa Coll. of Med., Iowa City, IA, USA
SO Abstracts of the Interscience Conference on Antimicrobial Agents and
Chemotherapy, (2000) Vol. 40, pp. 173. print.
Meeting Info.: 40th Interscience Conference on Antimicrobial Agents and
Chemotherapy. Toronto, Ontario, Canada. September 17-20, 2000.
DT Conference; (Meeting)
Conference; Abstract; (Meeting Abstract)
Conference; (Meeting Poster)
LA English
ED Entered STN: 13 Dec 2000
Last Updated on STN: 11 Jan 2002

L5 ANSWER 12 OF 14 CAPLUS COPYRIGHT 2006 ACS on STN
AN 2002:697737 CAPLUS
DN 137:385316
TI The apparent activation energy and relaxation volume from the point of
view of Adam-Gibbs theory
AU Solunov, Christo Al
CS University of Plovdiv "P Hilendarsky", Plovdiv, 4000, Bulg.
SO Journal of Physics: Condensed Matter (2002), 14(31), 7297-7309
CODEN: JCOMEL; ISSN: 0953-8984
PB Institute of Physics Publishing
DT Journal
LA English
RE.CNT 90 THERE ARE 90 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 13 OF 14 CAPLUS COPYRIGHT 2006 ACS on STN
AN 2002:293593 CAPLUS
DN 136:319398
TI Selective maxi-K-potassium channel openers functional under conditions of
high intracellular calcium concentration, methods and uses thereof
IN Gribkoff, Valentin K.; Post-Munson, Debra J.; Yeola, Sarita W.; Boissard,
Christopher G.; Hewawasam, Piyasena
PA Bristol-Myers Squibb Company, USA
SO PCT Int. Appl., 61 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1
PATENT NO. KIND DATE APPLICATION NO. DATE

```
     --------------     ----   --------    -------------------
--------
PI   WO 2002030868        A1    20020418    WO 2001-US32079
20011012
         W:  AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA,
CH, CN,
             CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD,
GE, GH,
             GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC,
LK, LR,
             LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ,
PH, PL,
             PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ,
UA, UG,
             UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
         RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE,
CH, CY,
             DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE,
TR, BF,
             BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD,
TG
     CA 2425771           AA    20020418    CA 2001-2425771
20011012
     US 2002045566        A1    20020418    US 2001-975881
20011012
     AU 2002013204        A5    20020422    AU 2002-13204
20011012
     EP 1330426           A1    20030730    EP 2001-981570
20011012
         R:  AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE,
MC, PT,
             IE, SI, LT, LV, FI, RO, MK, CY, AL, TR
     JP 2004511457        T2    20040415    JP 2002-534257
20011012
     US 2005043293        A1    20050224    US 2004-952523
20040928
PRAI US 2000-240146P      P     20001013
     US 2001-975881       A3    20011012
     WO 2001-US32079      W     20011012
RE.CNT  6     THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD
              ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5   ANSWER 14 OF 14  CAPLUS  COPYRIGHT 2006 ACS on STN
AN   1980:31984  CAPLUS
DN   92:31984
TI   Thermal fixing type toners
IN   Watanabe, Shotaro; Tozawa, Katsutoshi; Uetake, Shigeru
PA   Konishiroku Photo Industry Co., Ltd., Japan
SO   Jpn. Kokai Tokkyo Koho, 7 pp.
     CODEN: JKXXAF
DT   Patent
LA   Japanese
```

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO. DATE
PI	JP 54048556	A2	19790417	JP 1977-83567 19770714
	JP 58045022	B4	19831006	
PRAI	JP 1977-83567	A	19770714	

NCBI PubMed www.pubmed.gov

A service of the National Library of Medicine and the National Institutes of Health

My NCBI [Sign In] [Register]

All Databases PubMed Nucleotide Protein Genome Structure OMIM PMC Journals Books

Search PubMed for EphA2 inhibitor Go Clear Save Search

Limits Preview/Index History Clipboard Details

Display Summary Show 20 Sort by Send to

All: 5 Review: 1

Items 1 - 5 of 5 One page.

About Entrez
NCBI Toolbar

Text Version

Entrez PubMed Overview
Help | FAQ
Tutorials
New/Noteworthy
E-Utilities

PubMed Services
Journals Database
MeSH Database
Single Citation Matcher
Batch Citation Matcher
Clinical Queries
Special Queries
LinkOut
My NCBI

Related Resources
Order Documents
NLM Mobile
NLM Catalog
NLM Gateway
TOXNET
Consumer Health
Clinical Alerts
ClinicalTrials.gov
PubMed Central

1: Straume O, Akslen LA. Related Articles, Links

Strong expression of ID1 protein is associated with decreased survival, increased expression of ephrin-A1/EPHA2, and reduced thrombospondin-1 in malignant melanoma.
Br J Cancer. 2005 Oct 17;93(8):933-8.
PMID: 16189525 [PubMed - indexed for MEDLINE]

2: Xu H, Tian W, Lindsley JN, Oyama TT, Capasso JM, Rivard CJ, Cohen HT, Bagnasco SM, Anderson S, Cohen DM. Related Articles, Links

EphA2: expression in the renal medulla and regulation by hypertonicity and urea stress in vitro and in vivo.
Am J Physiol Renal Physiol. 2005 Apr;288(4):F855-66. Epub 2004 Nov 23.
PMID: 15561974 [PubMed - indexed for MEDLINE]

3: Cheng Q, Sasaki Y, Shoji M, Sugiyama Y, Tanaka H, Nakayama T, Mizuki N, Nakamura F, Takei K, Goshima Y. Related Articles, Links

Cdk5/p35 and Rho-kinase mediate ephrin-A5-induced signaling in retinal ganglion cells.
Mol Cell Neurosci. 2003 Nov;24(3):632-45.
PMID: 14664814 [PubMed - indexed for MEDLINE]

4: Hendrix MJ, Seftor EA, Kirschmann DA, Quaranta V, Seftor RE. Related Articles, Links

Remodeling of the microenvironment by aggressive melanoma tumor cells.
Ann N Y Acad Sci. 2003 May;995:151-61. Review.
PMID: 12814947 [PubMed - indexed for MEDLINE]

5: D'Amico TA, Aloia TA, Moore MB, Coulon DH, Herndon JE 2nd, Kinch MS, Harpole DH Jr. Related Articles, Links

Predicting the sites of metastases from lung cancer using molecular biologic markers.
Ann Thorac Surg. 2001 Oct;72(4):1144-8.
PMID: 11603427 [PubMed - indexed for MEDLINE]

Display Summary Show 20 Sort by Send to

1: Xu H, Tian W, Lindsley JN, Oyama TT, Capasso JM, Rivard CJ, Cohen HT, Bagnasco SM, Anderson S, Cohen DM. Related Articles, Links

EphA2: expression in the renal medulla and regulation by hypertonicity and urea stress in vitro and in vivo.
Am J Physiol Renal Physiol. 2005 Apr;288(4):F855-66. Epub 2004 Nov 23.
PMID: 15561974 [PubMed - indexed for MEDLINE]